GLP-1R Signaling and Functional Molecules in Incretin Therapy
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targeting GLP-1R have entered clinical treatment. However, novel functional molecules with reduced side effects and enhanced therapeutic efficacy are still in high demand. In this review, we summarize the basis of GLP-1R cellular signaling, and how it is involved in the treatment of T2DM. We review the functional molecules of incretin therapy in various stages of clinical trials. We also outline the current strategies and emerging techniques that are furthering the development of novel therapeutic drugs for T2DM and other metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Signaling pathways of GLP-1R in pancreatic β-cell [15,30]. Three downstream signaling pathways initiated from Gαs (blue), Gαq (pink), and β-arrestin (green) are shown in the left half of the β-cell. The GLP-1R internalization process and insulin secretion after GLP-1R activation are also shown. Colored circles show mono-agonists targeting GLP-1R (red), GIPR (green), and GCGR (blue), and multi-agonists targeting GLP-1R/GIPR (red/green), GLP-1R/GCGR (red/blue), and GLP-1R/GIPR/GCGR (red/green/blue). The top left inset shows the structure of GLP-1R with a seven-transmembrane helix bundle and a large ECD. Abbreviations: VDCC, voltage-dependent calcium channel; TRPM, the transient receptor potential melastatin; GCGR, glucagon receptor; GIPR, gastric inhibitory polypeptide receptor.](https://figures.cochat.ai/paper-figures/acbea23bdcdd42f9b5434df4875a1968/glp-1r-signaling-and-functional-molecules-in-incretin-therapy-figure-1.jpg)
![Figure 2 Development strategies for GLP-1R ligands [16,52,53]. (A) Amino acid sequences of GLP-1 (7-36) amide, exendin-4, and oxyntomodulin. Different residues from GLP-1 are in bold type. DPP-4 deactivates the GLP-1 (7-36) amide by cleaving it after the second amino acid (alanine) from the N-terminal and leads to the short circulation time of GLP-1 (7-36) in human body. (B) Several chemical modifications and their combinations can be applied in GLP-1R peptide agonist development, including C-terminal amidation, acylation, PEGylation, and substitution. (C) GLP-1R peptide ligands can fuse to Fc region of antibody, antibody, and albumin. (D) Three typical small-molecule agonists for GLP-1R: LY-3502970 and PF-06882961 are under clinical trials, while TT-OAD2 has failed.](https://figures.cochat.ai/paper-figures/974caae933284bd1bbb4d72559d12870/glp-1r-signaling-and-functional-molecules-in-incretin-therapy-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with GLP-1RAs can alleviate insulin signaling by reducing the phosphorylation of Akt protein (Decreased Akt-P) and activating Protein Kinase C-ε (PKC-ε).485,486”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [485]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9 · cited 1×
“A recent study reported that PX17, an updated agent based on P5, shows greater blood glucose modulation and body weight reduction compared with semaglutide [146].”
BackgroundRetracted10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“Two types of β-arrestin, β-arrestin-1 and β-arrestin-2, mediate the GLP-1R downstream signaling in β-cells, and also elicit the receptor internalization process. β-arrestin-1 mediates the phosphorylation of CREB and ERK1/2 [42], further phosphorylating Bad (Bcl-xL/Bcl-2-associated death promoter homolog) and inhibitin…”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 6×
“PF06882961 stays in the orthosteric binding pocket in the TMD, almost overlapping with the binding sites of the N-terminal of GLP-1 [28].”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“yethylene glycol (PEG) units to the peptide [58], while fatty acid acylation allows the co-”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Liraglutide Victoza Saxenda SC, qd T2DM Obesity 2010 2014 [68,69] [70] Dulaglutide Trulicity SC, qw T2DM 2014 [71]”
Background2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 2×
“Exenatide, the first approved GLP-1 analog, has significant effects on HbA1c level reduction [125], weight loss, and glycemic control [125], but no cardioprotective effect [67].”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 3×
“Due to initial concerns about potential risks in preclinical studies [8], they are not recommended for T2DM patients with diseases such as severe gastrointestinal disease, medullary carcinoma of the thyroid [131], multiple endocrine neoplasm syndrome type 2, and history of pancreatitis [126].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“At dosages of 5, 10, and 15 mg, tirzepatide showed non-inferior treatment in glycemic control and superior behavior in weight loss than 1 mg semaglutide [85], further demonstrating the therapeutic efficacy of multi-agonists.”
BackgroundOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · cited 1×
“Albiglutide Tanzeum SC, qw T2DM 2014 (withdrawal 2018) [72,73]”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Due to initial concerns about potential risks in preclinical studies [8], they are not recommended for T2DM patients with diseases such as severe gastrointestinal disease, medullary carcinoma of the thyroid [131], multiple endocrine neoplasm syndrome type 2, and history of pancreatitis [126].”
BackgroundSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Although not all the above adverse effects related to GLP-1R agonists treatment have been supported by recent evidence [142,143], further research and rigorous clinical trials examining the incidence of these events are still needed.”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“Byetta SC, bid T2DM 2005 [51,65,66] Exenatide Bydureon SC, qw T2DM 2012 [67]”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“3%) under the administration of GLP-1 [123].”
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Byetta SC, bid T2DM 2005 [51,65,66] Exenatide Bydureon SC, qw T2DM 2012 [67]”
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide Victoza Saxenda SC, qd T2DM Obesity 2010 2014 [68,69] [70] Dulaglutide Trulicity SC, qw T2DM 2014 [71]”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 3×
“8 mg liraglutide compared with glimepiride monotherapy [126].”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“Fortunately, exendin-4, a 39-amino acid peptide from Gila monster (Heloderma suspectum) venom, showed similar characteristics to the mammalian incretin hormone [49,50].”
BackgroundRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · cited 1×
“4 mg semaglutide, compared with daily 3 mg liraglutide, shows a superior effect on weight loss [129].”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“discovered an impaired incretin response in T2DM patients, leading to a decrease in incretin-stimulated insulin release [122].”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“Incretins were first discovered upon observing that oral glucose administration leads to greater insulinotropic effects than intravenous administration [7].”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“A series of phase 3 trials (Liraglutide Effect and Action in Diabetes, LEAD) was launched to compare the efficacy and safety between liraglutide and other oral antidiabetic drugs [69,126,127].”
BackgroundCardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · cited 2×
“In the case of Efpeglenatide, retinal safety, severe gastrointestinal events, and kidney function have attracted sustained attention [82].”
BackgroundMarre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724 · cited 1×
“As the largest receptor family, GPCRs are important drug targets for a broad range of indications [20].”
BackgroundG protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632 · cited 2×
“GLP-1R downstream signaling pathways network can be activated through coupling with the intracellular transducers [29].”
BackgroundSelf-citationRegulation of Insulin Secretion in Human Pancreatic Islets
Rorsman, P., & Braun, M. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183754 · Cited by 599 · cited 2×
“channels (VDCC), and causes Ca2+ influx [35,36].”
BackgroundGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · cited 1×
“However, these drugs can cause side effects such as hypoglycemia, weight gain, and cardiovascular risk [3].”
BackgroundDahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · cited 1×
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596 · cited 1×
“Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) trials showed the positive effects of subcutaneous semaglutide on glycemic control [128].”
BackgroundStrategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573 · cited 2×
“valent attachment of a fatty acid chain on the peptide [59] (Figure 2B).”
BackgroundcAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M., & Montminy, M. (2003) · Genes & Development · doi:10.1101/gad.1097103 · Cited by 543
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“However, due to the short circulation time of native GLP-1, it is infeasible to continuously administrate native GLP-1 for long-term blood glucose management [124].”
BackgroundNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 2×
“A further study identified that the reduction in GLP-1 accounted for the diabetic state [6].”
BackgroundPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498 · cited 1×
“Although not all the above adverse effects related to GLP-1R agonists treatment have been supported by recent evidence [142,143], further research and rigorous clinical trials examining the incidence of these events are still needed.”
BackgroundVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 1×
“Although GLP-1 has many potential advantages, its short circulation time of about 2 min [17] limits its application in treatment since such frequent administration is incompatible with patient compliance and thereby reducing drug effectiveness.”
BackgroundHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“Firstly, among all the adverse effects of GLP-1R agonist treatment, nausea and related gastrointestinal responses, such as vomiting and diarrhea, are the most common [132,133].”
BackgroundSuzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368 · cited 1×
“Second, the fusion protein can go through the neonatal Fc receptor (FcRn) recycling pathway [64].”
BackgroundHe, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356 · cited 1×
“Further, several concerns remain about the correlation of GLP1R agonist treatment with many other adverse events, including eye disorders such as retinopathy [138–140], and gallbladder- or biliary-related events [141].”
BackgroundSelf-citationFineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · cited 1×
“Exenatide, the first approved GLP-1 analog, has significant effects on HbA1c level reduction [125], weight loss, and glycemic control [125], but no cardioprotective effect [67].”
BackgroundGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
A Polypill Strategy to Improve Adherence
Castellano, J. M., Sanz, G., Peñalvo, J. L., Bansilal, S., Fernández-Ortiz, A., Alvarez, L., Guzmán, L., Linares, J. C., García, F., D’Aniello, F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.021 · Cited by 349
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346 · cited 2×
“Moreover, compared with exenatide, liraglutide carries a lower risk of cardiovascular death [120].”
BackgroundPolypill strategy in secondary cardiovascular prevention
Castellano, J. M., Pocock, S. J., Bhatt, D. L., Quesada, A. J., Owen, R., Fernandez-Ortiz, A., Sanchez, P. L., Marin Ortuño, F., Vazquez Rodriguez, J. M., Domingo-Fernández, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208275 · Cited by 334
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329 · cited 1×
“Although conventional diabetes diagnostic indicators such as fasting plasma glucose and HbA1c are simple and practicable, they do not provide the specificity to distinguish pathways related to pancreatic β-cell mass destruction or dysfunction [160,161].”
BackgroundØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325 · cited 1×
“The endogenous ligands of GLP-1R are GLP-1 (7-36) and GLP-1 (7-37), products from the post-translational processing of proglucagon [24].”
BackgroundPeptide chemistry toolbox – Transforming natural peptides into peptide therapeutics
Erak, M., Bellmann-Sickert, K., Els-Heindl, S., & Beck-Sickinger, A. G. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.012 · Cited by 324
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“Cotadutide (MEDI0382) / SC, qd T2DM NASH CKD Obesity Phase 2 Phase 2 Phase 2 Phase 1 [94] [95] [96] [97] Efinopegdutide (MK-6024) / SC, qw NASH Phase 2 /”
BackgroundFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315 · cited 2×
“activates adenylate cyclase (AC), and causes the accumulation of cAMP [33].”
BackgroundXie, J., Wang, M., Long, Z., Ning, H., Li, J., Cao, Y., Liao, Y., Liu, G., Wang, F., & Pan, A. (2022) · BMJ · doi:10.1136/bmj-2022-072385 · Cited by 300
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Moore, B., Edie, E. S., & Abram, J. H. (1906) · Biochemical Journal · doi:10.1042/bj0010028 · Cited by 279 · cited 1×
“used extracts from the duodenal mucous membrane to treat T2DM [121].”
MethodDahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 275 · cited 1×
“Despite the numerous anti-hyperglycemic agents that are already available on the market for T2DM treatment, there are still a surprising number of drug candidates in clinical trials, of which no less than 40% are with novel therapeutic molecules or targets [144,145].”
BackgroundTargeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272 · cited 1×
“Exendin-phe1, with minimal substitutions within the N-terminus of exendin-4, was found to promote glycemic benefits without decreasing tolerability [147].”
BackgroundPolypill with or without Aspirin in Persons without Cardiovascular Disease
Yusuf, S., Joseph, P., Dans, A., Gao, P., Teo, K., Xavier, D., López-Jaramillo, P., Yusoff, K., Santoso, A., Gamra, H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028220 · Cited by 270
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., et al. (2017) · Nature · doi:10.1038/nature22378 · Cited by 241 · cited 1×
“Due to a poor understanding of the ligand binding mode and activation mechanism prior to the first GLP-1R structure being solved in 2017 [101], high-throughput screening was adapted in many studies to identify promising candidates, followed by massive structure–activity relationship (SAR) studies to improve the chemic…”
BackgroundSelf-citationPeptide-Polymer Conjugates: From Fundamental Science to Application
Shu, J. Y., Panganiban, B., & Xu, T. (2013) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-040412-110108 · Cited by 238 · cited 2×
“renal filtration and enzymatic degradation due to steric hindrance [53,60].”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 2×
“As one of the first reported small molecules, compound 2 was extensively studied over the years and was characterized as an ago-PAM [114,115], a type of molecule that possesses functions of both agonist and PAM.”
BackgroundStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · cited 3×
“derivative and is a biased agonist that abolished β-arrestin signaling [103,112].”
BackgroundDifferential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.020 · Cited by 222
Montrose-Rafizadeh, C. (1999) · Endocrinology · doi:10.1210/en.140.3.1132 · Cited by 216
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Kang, G., Chepurny, O. G., & Holz, G. G. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0375c.xd · Cited by 204 · cited 2×
“With increasing cAMP levels, protein kinase A (PKA) [31] and the exchange rotein directly activated by cAMP-2 (Epac-2) [34] are also activated.”
BackgroundUrva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202 · cited 1×
“MOD6031 / SC, qw Obesity Phase 1 / GLP-1R/GCGR/GIPR HM-15211 / SC, qw NAFLD Phase 1 / LY-3437943 / SC, qw T2DM Phase 1 [99]”
Hepatic glucose sensing is required to preserve β cell glucose competence
Seyer, P., Vallois, D., Poitry‐Yamate, C., Schütz, F., Metref, S., Tarussio, D., Maechler, P., Staels, B., Lanz, B., Gruetter, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65538 · Cited by 193
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Self-citationPassing the baton in class B GPCRs: peptide hormone activation via helix induction?
Parthier, C., Reedtz-Runge, S., Rudolph, R., & Stubbs, M. T. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.004 · Cited by 191 · cited 1×
“The C-terminal α helix of peptide ligand initiates peptide recognition by binding to the ECD, then the peptide N-terminal can activate the receptor and trigger its downstream signaling cascade by binding to the transmembrane domain (TMD) ligandbinding pocket [25].”
BackgroundGLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189 · cited 1×
“PKC also triggers the closure of the KATP channel and activation of TRPM4/5 [40].”
BackgroundQuoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., & Dalle, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067207 · Cited by 187 · cited 1×
“mediates the phosphorylation of CREB and ERK1/2 [42], further phosphorylating Bad (Bcl-xL/Bcl-2-associated death promoter homolog) and inhibiting cell apoptosis [43].”
BackgroundVijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185 · cited 1×
“In the early stage of diabetes, metformin monotherapy is widely applied as the first-line drug and is generally sufficient for glycemic control in T2DM [118].”
BackgroundBattle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Retinal Imaging Techniques for Diabetic Retinopathy Screening
Goh, J. K. H., Cheung, C. Y., Sim, S. S., Tan, P. C., Tan, G. S. W., & Wong, T. Y. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816629491 · Cited by 174
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice
Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 169 · cited 1×
“One of the first small-molecule agonists, Boc5, is a substituted cyclobutane identified by HT screening [107].”
BackgroundActivation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164 · cited 5×
“The ECLs form an extracellular surface that interacts with orthosteric ligands.”
BackgroundInfluentialStructural basis of G s and G i recognition by the human glucagon receptor
Qiao, A., Han, S., Li, X., Li, Z., Zhao, P., Dai, A., Chang, R., Tai, L., Tan, Q., Chu, X., et al. (2020) · Science · doi:10.1126/science.aaz5346 · Cited by 160
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156 · cited 1×
“Danuglipron (PF-06882961) bid T2DM obesity Phase 2 Phase 2 [102]”
BackgroundNovel therapies with precision mechanisms for type 2 diabetes mellitus
Perreault, L., Skyler, J. S., & Rosenstock, J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00489-y · Cited by 155 · cited 2×
“Pancreatic β-cell dysfunction and resultant insulin deficiency are the key features of T2DM [4], however, most medications do not target β-cell and become less effective as diabetes progress [5].”
BackgroundReal-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153 · cited 2×
“A portion of that is eventually transported to lysosomes for degradation, while the other portion returns to the cell membrane [46].”
BackgroundBethel, M. A., Diaz, R., Castellana, N., Bhattacharya, I., Gerstein, H. C., & Lakshmanan, M. C. (2021) · Diabetes Care · doi:10.2337/dc20-1815 · Cited by 151
Kuna, R. S., Girada, S. B., Asalla, S., Vallentyne, J., Maddika, S., Patterson, J. T., Smiley, D. L., DiMarchi, R. D., & Mitra, P. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2012 · Cited by 150
Full-length human GLP-1 receptor structure without orthosteric ligands
Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G. W., Ren, Q., Roed, N. K., Lin, G., Hanson, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14934-5 · Cited by 148 · cited 1×
“GLP-1R, together with four other glucagon receptors (GCGR, GLP-2R, GIPR, and GHRHR), belongs to the secretin (class B1) GPCR family, whose endogenous ligands are peptide hormones [21,22].”
BackgroundSelf-citationGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144 · cited 1×
“Albiglutide Tanzeum SC, qw T2DM 2014 (withdrawal 2018) [72,73]”
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · cited 1×
“by BETP was identified by screening a small library generated through a pharmacophore model [116].”
MethodAutocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T. M., Turn, R. E., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 143 · cited 2×
“exendin-4 (HGEGTFTS) with novel sequence ELVDNAVGG, the modified agent named P5, was a potent and selective biased GLP-1 agonist that was investigated, which was found to have a higher acute anti-hyperglycemia efficacy than exendin-4 [135].”
BackgroundSelf-citationTCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142 · cited 1×
“Instead of playing a redundant role, GIP may protect β-cells from dysfunction and destruction independently of GLP-1 [83].”
BackgroundSelf-citationAroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135 · cited 1×
“With transcellular permeation enhancers, peptide-based GLP-1R agonists may also be taken orally [152].”
BackgroundExtending the Structural View of Class B GPCRs
de Graaf, C., Song, G., Cao, C., Zhao, Q., Wang, M.-W., Wu, B., & Stevens, R. C. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.10.003 · Cited by 133 · cited 1×
“Class B1 GPCRs have a large and structurally conserved extracellular domain (ECD) of 120–160 residues at the N-terminal, forming a three-layered α-β-β-α fold that is stabilized by three interlayer disulfide bonds [23].”
BackgroundSelf-citationA Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133 · cited 1×
“Oral semaglutide administered once per week showed favorable efficacy and safety in the treatment of T2DM patients and the large, randomized control clinical trial is ongoing [130].”
BackgroundGIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132 · cited 1×
“Although both GLP-1 and GIP could promote insulin secretion in a healthy state, the therapeutic potential of GIP alone is controversial [9,10].”
BackgroundParker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123 · cited 1×
“Cotadutide (MEDI0382) / SC, qd T2DM NASH CKD Obesity Phase 2 Phase 2 Phase 2 Phase 1 [94] [95] [96] [97] Efinopegdutide (MK-6024) / SC, qw NASH Phase 2 /”
BackgroundMarzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121 · cited 6×
“PKA and Epac-2 trigger the closure of KATP and KV channels, which depolarizes the cell m mbrane, p ns voltage- ependent calcium channels (VDCC), and causes Ca2+ influx [35,36].”
BackgroundInfluentialGs/Gq signaling switch in β cells defines incretin effectiveness in diabetes
Oduori, O. S., Murao, N., Shimomura, K., Takahashi, H., Zhang, Q., Dou, H., Sakai, S., Minami, K., Chanclón, B., Guida, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140046 · Cited by 118 · cited 3×
“A switch of Gαs and Gαq pathways has been found under certain conditions, including persistent depolarization of cell membrane [30], and reduction in GLP-1 concentration to picomolar [41].”
BackgroundNon-canonical β-adrenergic activation of ERK at endosomes
Kwon, Y., Mehta, S., Clark, M. J., Walters, G., Zhong, Y., Lee, H. N., Sunahara, R. K., & Zhang, J. (2022) · Nature · doi:10.1038/s41586-022-05343-3 · Cited by 117 · cited 1×
“The latest study suggested that internalized endosomal GPCRGαs complexes are the origin of induced ERK activity [48], but the detailed mechanism remains implicit.”
BackgroundA Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo
Johnson, L. M., Barrick, S., Hager, M. V., McFedries, A., Homan, E. A., Rabaglia, M. E., Keller, M. P., Attie, A., Saghatelian, A., Bisello, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507168t · Cited by 108
Kang, G., Leech, C. A., Chepurny, O. G., Coetzee, W. A., & Holz, G. G. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2007.143818 · Cited by 108 · cited 2×
“channels (VDCC), and causes Ca2+ influx [35,36].”
BackgroundThe therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 107 · cited 1×
“Secondly, the roles of GLP-1R agonists in promoting the proliferation of β-cells and reducing their apoptosis could increase the risk of pancreatic cancer [136,137].”
BackgroundZhu, L., Almaça, J., Dadi, P. K., Hong, H., Sakamoto, W., Rossi, M., Lee, R. J., Vierra, N. C., Lü, H., Cui, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14295 · Cited by 94 · cited 1×
“Knocking out β-arrestin-2 in the mice model and leading to impaired insulin secretion [44].”
BackgroundYap, M. K. K., & Misuan, N. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 92 · cited 1×
“Fortunately, exendin-4, a 39-amino acid peptide from Gila monster (Heloderma suspectum) venom, showed similar characteristics to the mammalian incretin hormone [49,50].”
BackgroundTransformation of Oligomers of Lipidated Peptide Induced by Change in pH
Wang, Y., Lomakin, A., Kanai, S., Alex, R., & Benedek, G. B. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500519s · Cited by 90
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86 · cited 2×
“In order to develop safer therapeutic drugs, it is essential to study the mechanism of these dual and triple agonists [88] from structural, functional, and pharmacologic aspects.”
BackgroundObesity, metabolic disease and the pancreas—Quantitative imaging of pancreatic fat
Sakai, N. S., Taylor, S. A., & Chouhan, M. D. (2018) · The British Journal of Radiology · doi:10.1259/bjr.20180267 · Cited by 86
Structure and Function of Peptide-Binding G Protein-Coupled Receptors
Wu, F., Song, G., de Graaf, C., & Stevens, R. C. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.022 · Cited by 85 · cited 1×
“GLP-1R, together with four other glucagon receptors (GCGR, GLP-2R, GIPR, and GHRHR), belongs to the secretin (class B1) GPCR family, whose endogenous ligands are peptide hormones [21,22].”
BackgroundSelf-citationLind, M., JENDLE, J. H., Torffvit, O., & Lager, I. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.09.002 · Cited by 80
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80 · cited 1×
“Cotadutide (MEDI0382) / SC, qd T2DM NASH CKD Obesity Phase 2 Phase 2 Phase 2 Phase 1 [94] [95] [96] [97] Efinopegdutide (MK-6024) / SC, qw NASH Phase 2 /”
BackgroundOligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations
Frederiksen, T. M., Sønderby, P., Ryberg, L. A., Harris, P., Bukrinski, J. T., Scharff‐Poulsen, A. M., Elf-Lind, M. N., & Peters, G. H. J. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.07.051 · Cited by 72
Baumgartner, A., Drame, K., Geutjens, S., & Airaksinen, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020190 · Cited by 71
Structural and functional diversity among agonist-bound states of the GLP-1 receptor
Cary, B. P., Deganutti, G., Zhao, P., Truong, T. T., Piper, S. J., Liu, X., Belousoff, M. J., Danev, R., Sexton, P. M., Wootten, D. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00945-w · Cited by 68 · cited 1×
“Structure and functional studies, aided by molecular dynamics simulation, illustrate that the peptide agonist conformation plasticity, especially the dynamic interaction of the receptor with the N-terminal activation domain of the peptide, may be an essential determinant for agonist efficacy [148].”
BackgroundLongato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 62 · cited 1×
“However, GLP-1R agonists are favored because they have superior body weight control [18] and cardiovascular outcomes [19].”
BackgroundA role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion
Shigeto, M., Cha, C. Y., Rorsman, P., & Kaku, K. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1508-6 · Cited by 59 · cited 1×
“A switch of Gαs and Gαq pathways has been found under certain conditions, including persistent depolarization of cell membrane [30], and reduction in GLP-1 concentration to picomolar [41].”
BackgroundEid, L. E., Reynolds, C. A., Tomás, A., & Jones, B. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106411 · Cited by 57 · cited 2×
“Firstly, among all the adverse effects of GLP-1R agonist treatment, nausea and related gastrointestinal responses, such as vomiting and diarrhea, are the most common [132,133].”
BackgroundJiang, H., Pang, S., Zhang, Y., Yu, T., Liu, M., Deng, H., Li, L., Feng, L., Song, B., Han-Zhang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31328-x · Cited by 50 · cited 1×
“Mazdutide (IBI-362) / SC, qw T2DM Obesity Phase 2 Phase 1 / [98]”
Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling
Bavec, A., Hällbrink, M., Langel, Ü., & Zorko, M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00282-3 · Cited by 49 · cited 2×
“protein subtypes including Gαi, Gαq, Gαo, and Gα11 [38,39].”
BackgroundZhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol
Gooding, K. M., Lienczewski, C., Papale, M., Koivuviita, N. S., Maziarz, M., Andersson, A. D., Sharma, K., Pontrelli, P., Hernandez, A. G., Bailey, J., et al. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01901-x · Cited by 49
Schiavon, M., Visentin, R., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14394 · Cited by 49 · cited 1×
“SAR425899 / SC, qd T2DM Phase 2 (discontinued) [93]”
Zhao, F., Zhang, C., Zhou, Q., Hang, K., Zou, X., Chen, Y., Wu, F., Rao, Q., Dai, A., Yin, W., et al. (2021) · eLife · doi:10.7554/elife.68719 · Cited by 49
Self-citationFang, Z., Chen, S., Manchanda, Y., Bitsi, S., Pickford, P., David, A., Shchepinova, M. M., Corrêa Jr, I. R., Hodson, D. J., Broichhagen, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218404 · Cited by 44 · cited 1×
“For example, GLP-1 is apt to receptor recycling, while exendin-4 may favor slower recycling and lysosome targeting [47].”
BackgroundPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43 · cited 1×
“OXM can naturally activate both GCGR and GLP-1R with lower potency than their primary ligands [87].”
BackgroundCong, Z., Zhou, Q., Li, Y., Chen, L.-N., Zhang, Z.-C., Liang, A., Liu, Q., Wu, X., Dai, A., Xia, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200155119 · Cited by 43 · cited 1×
“Finally, a Boc5 binding structure is published recently, which shows that Boc5 adapts a claw shape in its binding pocket, with three fingers stuck into the slits between TM1-TM3 and TM7 [113].”
BackgroundRadiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes
Hernandez, R. T., Graves, S. A., Gregg, T., VanDeusen, H. R., Fenske, R. J., Wienkes, H. N., England, C. G., Valdovinos, H. F., Jeffery, J. J., Barnhart, T. E., et al. (2017) · Diabetes · doi:10.2337/db16-1285 · Cited by 42
Infante‐Garcia, C., Ramos‐Rodríguez, J. J., Hierro‐Bujalance, C., Ortegon, E., Pickett, E. K., Jackson, R. J., Pacho, F. H., Spires‐Jones, T. L., & García-Alloza, M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0825-7 · Cited by 42 · cited 1×
“Moreover, polypill (fixed-low-dose combination drug) can also help by simplifying medication [153–156] and, if oral antidiabetic drugs were included in the polypill formulation, diabetic patients would further benefit [157,158].”
BackgroundMalik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41 · cited 1×
“Although their half-lives can be prolonged by the strategies discussed above, problems or limits such as cost, side effects, and subcutaneous injection remain [100].”
BackgroundLu, Y., Qin, S., Zhang, B., Dai, A., Cai, X., Ma, M., Gao, Z.-G., Yang, D., Stevens, R. C., Jacobson, K. A., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00477 · Cited by 39 · cited 1×
“technology, such as affinity selective mass spectrometry (ASMS), could promote the discovery of lead compounds from natural products that act as reservoirs of novel therapeutic agents [29,150,151].”
BackgroundSelf-citationCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39 · cited 2×
“Recent studies have reported strategies, which altered the brain penetration property of GLP-1R agonists, to mitigate nausea or other unwanted gastrointestinal responses, the most prominent adverse effects of GLP-1R agonist treatment [134,149].”
Backgroundβ Cell–intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion
Barella, L. F., Rossi, M., Zhu, L., Cui, Y., Mei, F. C., Cheng, X., Chen, W., Gurevich, V. V., & Wess, J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126309 · Cited by 38
Huang, L. T., Zhang, Q., Tang, T., Yang, M., Chen, C., Tao, J., & Liang, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.693890 · Cited by 36
Rosenstock, J., Sorli, C. H., Trautmann, M. E., Morales, C., Wendisch, U., Dailey, G., Hompesch, M., Choi, I. Y., Kang, J., Stewart, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2648 · Cited by 34 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Luo, K., Huang, W., Qiao, L., Zhang, X., Yan, D., Ning, Z.-Y., Ma, C., Dang, H., Wang, D., Guo, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.017 · Cited by 34 · cited 1×
“technology, such as affinity selective mass spectrometry (ASMS), could promote the discovery of lead compounds from natural products that act as reservoirs of novel therapeutic agents [29,150,151].”
BackgroundSelf-citationMagnetic resonance imaging of diabetic foot complications
Low, K., & Peh, W. (2015) · Singapore Medical Journal · doi:10.11622/smedj.2015006 · Cited by 33
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
Liu, C., Zou, Y., & Qian, H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811851 · Cited by 32 · cited 1×
“Development strategies for GLP-1R ligands [16,52,53].”
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 29 · cited 1×
“Noninvasive imaging tools (such as PET and MRI) and novel biomarkers can provide abundant pathological characteristics about β-cells [162–166] or related diagnostic information [140,167–173], which may help improve monitoring disease progress and severity, support the development of diabetes management strategies, eva…”
BackgroundAerobic glycolysis imaging of epileptic foci during the inter-ictal period
Zhang, M., Qin, Q., Zhang, S., Liu, W., Meng, H., Xu, M., Huang, X., Lin, X., Mu, L., Hermán, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104004 · Cited by 29
Self-citationFrom Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Dicembrini, I., Pala, L., & Rotella, C. M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/898913 · Cited by 26 · cited 1×
“However, GLP-1R agonists are favored because they have superior body weight control [18] and cardiovascular outcomes [19].”
BackgroundBorner, T., Shaulson, E. D., Tinsley, I. C., Stein, L. M., Horn, C. C., Hayes, M. R., Doyle, R. P., & Jonghe, B. C. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14089 · Cited by 25 · cited 3×
“Recent studies have reported strategies, which altered the brain penetration property of GLP-1R agonists, to mitigate nausea or other unwanted gastrointestinal responses, the most prominent adverse effects of GLP-1R agonist treatment [134,149].”
BackgroundBini, J., Naganawa, M., Nabulsi, N., Huang, Y. H., Ropchan, J. R., Lim, K., Najafzadeh, S., Herold, K. C., Cline, G. W., & Carson, R. E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197285 · Cited by 24
Willard, F. S., Wainscott, D. B., Showalter, A. D., Stutsman, C., Ma, W., Cardona, G. R., Zink, R. W., Corkins, C. M., Chen, Q., Yumibe, N. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00029 · Cited by 23 · cited 1×
“Recently, a new ago-PAM, LSN3318839, was reported to restore the activity of GLP-1 (9-39) [117].”
BackgroundAli, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01031-5 · Cited by 23 · cited 1×
“Several OXM derivatives are under clinical trials, for example, cotadutide, a once-daily GCGR/GLP1R dual agonist, has shown promising impacts on glycemic control, body weight, and liver fat reduction [89].”
BackgroundBurtéa, C., Laurent, S., Crombez, D., Delcambre, S., Sermeus, C., Millard, I., Rorive, S., Flamez, D., Beckers, M., Salmon, I. J., et al. (2015) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1641 · Cited by 22
Zou, X., Huang, Q., Luo, Y., Ren, Q., Han, X., Zhou, X., & Ji, L. (2022) · Diabetologia · doi:10.1007/s00125-022-05748-9 · Cited by 22 · cited 1×
“Artificial intelligence (AI) is likely to play an increasingly important role in diabetes diagnosis (such as medical image analysis and subtype classification), clinical decision support, management, risk identification, prevention [133–136], and prognosis [176].”
Background68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma
Li, L., Zhao, R., Hong, H., Li, G., Zhang, Y., Luo, Y., Zha, Z., Zhu, J., Qiao, J., Zhu, L., et al. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.10.001 · Cited by 16
Combined use of polypill components in patients with type 2 diabetes mellitus
Janssen, V. E., Visseren, F. L. J., de Boer, A., Grobbee, D. E., Westerink, J., van der Graaf, Y., & Lafeber, M. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318789494 · Cited by 15 · cited 1×
“Moreover, polypill (fixed-low-dose combination drug) can also help by simplifying medication [153–156] and, if oral antidiabetic drugs were included in the polypill formulation, diabetic patients would further benefit [157,158].”
BackgroundBeta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
Demine, S., Schulte, M. I., Territo, P. R., & Eizirik, D. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197274 · Cited by 15
New developments in the prospects for GLP‐1 therapy
Trapp, S., & Stanford, S. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15788 · Cited by 14 · cited 1×
“Despite the numerous anti-hyperglycemic agents that are already available on the market for T2DM treatment, there are still a surprising number of drug candidates in clinical trials, of which no less than 40% are with novel therapeutic molecules or targets [144,145].”
BackgroundJi, L., Du, Y., Xu, M., Zhou, X., Mo, Z., Ma, J., Li, J., Li, Y., Lin, J., Wang, Y., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05392-9 · Cited by 12 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12
Diamanti, K., Visvanathar, R., Pereira, M. J., Cavalli, M., Pan, G., Kumar, C., Skrtic, S., Risérus, U., Eriksson, J. W., Kullberg, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64524-0 · Cited by 10
News ways of understanding the complex biology of diabetes using PET
Eriksson, O., Långström, B., & Antoni, G. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.04.004 · Cited by 6 · cited 1×
“Noninvasive imaging tools (such as PET and MRI) and novel biomarkers can provide abundant pathological characteristics about β-cells [162–166] or related diagnostic information [140,167–173], which may help improve monitoring disease progress and severity, support the development of diabetes management strategies, eva…”
BackgroundKumar, D., Eipper, B. A., & Mains, R. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.04040-x · Cited by 6
PIRNER, M. A., LIN, J., LIU, F., YAO, L., Zettler, M. E., & Valacer, D. J. (2022) · Diabetes · doi:10.2337/db22-94-lb · Cited by 2
Research works printed but not linked: 1
- Buckeridge, 2022, Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity, Diabetologia, 65, S60
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“485,486 This affects the synthesis of triacylglycerol (TAG), phosphatidic acid (di-P PA), and diacylglycerol (DAG) in the liver.”
BackgroundRhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
“This canonical pathway promotes insulin granule exocytosis while simultaneously suppressing inappropriate glucagon secretion from α -cells [51,52].”
Cryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins
Cong, Z., Zhao, F., Li, Y., Luo, G., Mai, Y., Chen, X., Chen, Y., Lin, S., Cai, X., Zhou, Q., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00649-0 · Cited by 31
Metadata
- Authors
- Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y.
- Affiliations
- ShanghaiTech University (CN)
- Structure Therapeutics, South San Francisco, CA 94080, USA
- Corresponding author
- Stevens, Raymond C.
- Liu, Yan
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2023-01-11
- Volume
- 28
- Issue
- 2
- Pages
- 751
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC9866634
- OpenAlex
- W4315781708
- Cited by
- 44
- References
- 168
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 12 · 2023: 6
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- ShanghaiTech University (21ZR1442500)
- Shanghai Municipal Government (21ZR1442500)
- Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University (21ZR1442500)
- Science and Technology Commission of Shanghai Municipality (21ZR1442500)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, incretin-based therapy, type 2 diabetes, insulin secretion, blood glucose regulation, GLP-1 receptor agonists, GLP-1 receptor antagonists, drug development, metabolic disorders
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Insulin, Signal Transduction, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.